<DOC>
	<DOCNO>NCT01261000</DOCNO>
	<brief_summary>Acromegaly disease pituitary gland involve overproduction growth hormone . The drug work block bind growth hormone growth hormone receptor find tissue throughout body . Human study evaluate reduction IGF-I level blood follow pegvisomant treatment , however , study evaluate IGF-I level tissue follow pegvisomant administration . In study , test novel tissue biomarker pegvisomant action , distinct measure IGF-I level blood . To end , determine administration pegvisomant modifies expression IGF-I , IGF-I receptor , growth hormone receptor GH- IGF-i-dependent signal molecule colon tissue patient acromegaly .</brief_summary>
	<brief_title>Tissue Biomarker Pegvisomant Action</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<criteria>The subject provide write informed consent prior study related procedure The patient age 18 80 year inclusive The patient male female . If woman risk become pregnant , must agree use effective method contraception include implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomize partner .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Acromegaly</keyword>
</DOC>